The 2019 Global Epilepsy Drugs Market - $9+ Billion Forecast to 2025: Vimpat, Keppra and Epidiolex are Playing a Significant Role - ResearchAndMarkets.com
The "Epilepsy Drugs Market by Country (US, UK, France, etc), Drugs (Vimpat, Keppra, Sabril, Onfi, etc), Treatment Drugs Generation (First, Second, Third), Companies & Forecast" report has been added to ResearchAndMarkets.com's offering.
This report provides a complete analysis of Global Epilepsy Drugs Market. This report also covers all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.
The global epilepsy drugs market is expected to cross US$ 9 Billion landmark by 2025. Epilepsy prevalence varies across various parts of the world. At present, nearly one-third of the total patients are suffering from uncontrollable seizures and are not able to get treatment because no available treatment works for them.
The factors that are driving the global Epilepsy drug market are increasing epilepsy prevalence, growing patient awareness programs, government funding and drugs reimbursement options in European & American countries. Recently, anti-epilepsy drugs Epidiolex approvals for pediatric epilepsies, namely Lennox-Gastaut syndrome and Dravet syndrome in the United States will also help in the growth of Epilepsy drug market during the forecast period as well.
By Country - United States is Dominating Global Epilepsy Drugs Market
The report studies the market of the following countries: United States, United Kingdom, France, Germany, Italy, Spain, India, China, and Japan. The United States is dominating the global epilepsy drugs market. Its share is expected to grow in the years to come due to the better healthcare support system, growing awareness and increasing per capita healthcare expenditure.
By Drugs - Vimpat (Lacosamide), Keppra (Levetiracetam) and Epidiolex are playing a significant role
The report studies the market of the following drugs: Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089). At present, Vimpat (Lacosamide) and Keppra (Levetiracetam) are playing a significant role in the epilepsy treatment. Epidiolex has a bright future ahead.
By Drugs Category - Second and Third Generation Plays the Significant Role
In this report, we have categorized the epilepsy drugs market into three generations; First Generation, Second Generation, Third Generation. It is anticipated that the second and third generation plays a significant role in the global epilepsy drugs market during the forecast period of 2019-2025.
Eisai, UCB, H. Lundbeck A/S, and GW Pharmaceuticals PLC are some of the top companies that deal efficiently in epilepsy business globally. These companies have been studied thoroughly in the report.
Key Topics Covered
1.1 Market Definition
1.2 Currency Conversion
2. Research Methodology
3. Executive Summary
4. Global Epilepsy Drugs Market (2013 - 2025)
5. Market Share - Global Epilepsy Drugs (2013 - 2025)
5.1 By Country
5.2 By Drugs Category
5.3 By Drugs
6. Country - Global Epilepsy Drugs Market Analysis (2013 - 2025)
6.1 United States
6.2 United Kingdom
7. By Drugs Category - Global Epilepsy Drugs Market Analysis (2013 - 2025)
7.1 First Generation
7.2 Second Generation
7.3 Third Generation
8. By Drugs - Global Epilepsy Drugs Market Analysis (2013 - 2025)
8.1 Vimpat (Lacosamide)
8.2 Keppra (Levetiracetam)
8.3 Sabril (Vigabatrin)
8.4 Onfi (Clobazam)
8.6 Briviact (Brivaracetam)
8.8 Cenobamate (YKP3089)
9. Growth Drivers
9.1 Growing Awareness Programs Worldwide
9.2 Presence of Promising Pipeline for Epilepsy Therapeutics
10.1 New Restrictions on Epilepsy Drug
10.2 High Cost of Antiepileptic Drugs
11. Eisai Co. Ltd.
11.1 Company Overview
11.2.1 Point 1
11.2.2 Point 2
11.2.3 Point 3
11.3 Financial Insight
12. UCB Inc.
12.1 Company Overview
12.2.1 Point 1
12.2.2 Point 2
12.2.3 Point 3
12.2.4 Point 4
12.3 Financial Insight
13. H. Lundbeck A/S
13.1 Company Overview
13.2.1 Point 1
13.2.2 Point 2
13.2.3 Point 3
13.3 Financial Insight
14. GW Pharmaceuticals PLC
14.1 Company Overview
14.2.1 Point 1
14.2.2 Point 2
14.3 Financial Insight
For more information about this report visit https://www.researchandmarkets.com/research/dtvs63/the_2019_global?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190204005398/en/